⁶⁸Ga-FAPI PET/CT、¹⁸F-FDG PET/CT与乳腺MRI评估乳腺癌肿瘤范围及腋窝转移的诊断效能
该回顾性研究以术后病理为参考标准,纳入60例未接受新辅助化疗的浸润性乳腺癌患者,比较⁶⁸Ga-FAPI PET/CT、¹⁸F-FDG PET/CT与乳腺MRI评估原发肿瘤大小、乳腺内多灶/多中心病变及腋窝淋巴结转移的诊断效能。结果显示MRI与FAPI PET/CT对肿瘤大小的相关性最强,FAPI PET/CT对腋窝淋巴结转移特异性达100.0%,并可检出FDG PET/CT未发现的转移病灶。
要点
- MRI(ρ=0.866)与⁶⁸Ga-FAPI PET/CT(ρ=0.844)对病理肿瘤大小的相关性优于¹⁸F-FDG PET/CT(ρ=0.780)。
- ⁶⁸Ga-FAPI PET/CT对腋窝淋巴结转移的敏感性81.2%、特异性100.0%,优于¹⁸F-FDG PET/CT(敏感性43.8%)。
- ⁶⁸Ga-FAPI PET/CT可检出¹⁸F-FDG PET/CT未发现的腋窝淋巴结、乳腺内病灶及远处转移。
核心结论
- ⁶⁸Ga-FAPI PET/CT对原发肿瘤大小评估及多灶/多中心病变检出的诊断效能高于¹⁸F-FDG PET/CT,与乳腺MRI相当。
- ⁶⁸Ga-FAPI PET/CT对腋窝淋巴结转移评估的特异性高于MRI,并可检出¹⁸F-FDG PET/CT未发现的转移病灶,支持其作为MRI补充模态或特定患者的替代功能成像技术。
研究设计与样本
- 回顾性研究,纳入60例接受全乳切除术且未接受新辅助化疗的浸润性乳腺癌患者。
- 所有患者术前均行⁶⁸Ga-FAPI PET/CT、¹⁸F-FDG PET/CT及乳腺MRI,以术后病理为参考标准。
主要发现
- MRI(ρ=0.866)和⁶⁸Ga-FAPI PET/CT(ρ=0.844)与病理肿瘤大小的相关性最强,¹⁸F-FDG PET/CT较低(ρ=0.780)。
- 乳腺MRI(45.0%)和⁶⁸Ga-FAPI PET/CT(38.3%)检出多灶或多中心病变显著优于¹⁸F-FDG PET/CT(18.3%)(p < 0.001)。
- 腋窝淋巴结转移检测中,乳腺MRI敏感性最高(87.5%)但特异性较低(72.7%);⁶⁸Ga-FAPI PET/CT敏感性81.2%、特异性100.0%;¹⁸F-FDG PET/CT敏感性43.8%、特异性93.2%。
- ⁶⁸Ga-FAPI PET/CT检出¹⁸F-FDG PET/CT未发现的7枚腋窝淋巴结(11.7%)、29个额外乳腺内肿瘤灶(48.3%)及4处远处转移(6.7%)。
关键数值与推荐
- 多灶/多中心病变检出率:乳腺MRI 45.0%,⁶⁸Ga-FAPI PET/CT 38.3%,¹⁸F-FDG PET/CT 18.3%(p < 0.001)。
- 腋窝淋巴结转移诊断:MRI敏感性87.5%、特异性72.7%;⁶⁸Ga-FAPI PET/CT敏感性81.2%、特异性100.0%;¹⁸F-FDG PET/CT敏感性43.8%、特异性93.2%。
- 肿瘤大小与病理相关性:MRI ρ=0.866,⁶⁸Ga-FAPI PET/CT ρ=0.844,¹⁸F-FDG PET/CT ρ=0.780。
临床怎么用
- 在未接受新辅助化疗的浸润性乳腺癌患者中,⁶⁸Ga-FAPI PET/CT可用于辅助评估原发肿瘤大小及多灶/多中心病变。
- ⁶⁸Ga-FAPI PET/CT对腋窝淋巴结转移的高特异性有助于减少假阳性,并可检出¹⁸F-FDG PET/CT未发现的转移病灶。
- ⁶⁸Ga-FAPI PET/CT可作为乳腺MRI的补充模态或特定患者的功能成像替代选择。
局限性
- 回顾性研究设计,样本量60例,可能存在选择偏倚。
- 仅纳入接受全乳切除术且未接受新辅助化疗的患者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the diagnostic performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and magnetic resonance imaging (MRI) in assessing primary tumor size, detecting additional intramammary foci, and identifying axillary lymph node metastasis (ALNM) in patients with invasive breast cancer (IBC) undergoing upfront surgery without neoadjuvant chemotherapy (NAC), using postoperative histopathology as the reference standard. METHODS: This retrospective study included 60 IBC patients who underwent total mastectomy without NAC. All patients had preoperative ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and breast MRI. Primary tumor size, multifocality/multicentricity (MF/MC), and ALNM were evaluated for each modality. FAPI and FDG were additionally assessed for extra-axillary lymph nodes, internal mammary nodes, and distant metastases. Agreement between imaging- and pathology-based tumor size measurements, as well as the diagnostic performance for MF/MC and ALNM, were evaluated using correlation analyses and standard diagnostic accuracy metrics. RESULTS: MRI (ρ = 0.866) and ⁶⁸Ga-FAPI PET/CT (ρ = 0.844) demonstrated the strongest correlation with pathologic tumor size, whereas ¹⁸F-FDG PET/CT showed lower agreement (ρ = 0.780). Breast MRI (45.0%) and ⁶⁸Ga-FAPI-PET/CT (38.3%) were significantly superior to ¹⁸F-FDG PET/CT (18.3%) in detecting multifocal or multicentric disease (p < 0.001). For ALNM detection, breast MRI achieved the highest sensitivity (87.5%) but showed lower specificity (72.7%). In contrast, ⁶⁸Ga-FAPI PET/CT combined high sensitivity (81.2%) with perfect specificity (100.0%), outperforming ¹⁸F-FDG PET/CT, which demonstrated lower sensitivity (43.8%) despite high specificity (93.2%). Additionally, ⁶⁸Ga-FAPIPET/CT identified metastatic findings not detected by ¹⁸F-FDG PET/CT, including seven axillary lymph nodes (11.7%), 29 additional intramammary tumor foci (48.3%), and four distant metastases (6.7%). CONCLUSION: ⁶⁸Ga-FAPI PET/CT demonstrated higher diagnostic performance than ¹⁸F-FDG PET/CT and accuracy comparable to breast MRI for primary tumor size estimation and detection of multifocal or multicentric disease. FAPI-PET/CT also provided higher specificity than MRI for ALNM assessment and identified additional metastatic lesions not detected by FDG-PET/CT, supporting its potential role as a complementary modality to MRI and an alternative functional imaging technique in selected patients.
引用
- Tekcan Sanli DE, Elboga U, Yerdes E, et al. Diagnostic Performance of ⁶⁸Ga-FAPI PET/CT, ¹⁸F-FDG PET/CT, and Breast MRI for Assessing Tumor Extent and Axillary Metastasis in Breast Cancer: A Histopathology-Referenced Retrospective Study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42297929. doi:10.1007/s00259-026-07953-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。